| Editor's note: A technical problem prevented distribution of this edition as scheduled Tuesday afternoon. We apologize for the delay. Featured Story | Tuesday, June 16, 2020 After a groundbreaking study proved the decades-old, inexpensive steroid dexamethasone can reduce COVID-19 deaths among hospitalized patients requiring oxygen, the U.K. government granted a world-first approval. The speedy OK—just hours after researchers released their data—follows the FDA's revoking its emergency nod for the much-ballyhooed malaria drug hydroxychloroquine. read more |
| |
|---|
|
Top Stories Monday, June 15, 2020 Ask almost any physician about the outlandish medical theories they’ve heard, and they’ll probably ask you how much time you’ve got. But COVID-19 has brought a whole new meaning to the term "conspiracy theory." read more Tuesday, June 16, 2020 AstraZeneca, advancing a COVID-19 vaccine from the University of Oxford, is among global frontrunners in the worldwide hunt for a viable vaccine. But the drugmaker’s CEO now says the vaccine will only provide protection for about a year. read more Tuesday, June 16, 2020 As the U.S., Germany and France start funneling more cash into their life sciences for a solution to the COVID-19 problem, the U.K. is following suit with a new type of vaccine. read more Tuesday, June 16, 2020 China's state-run Sinopharm said one of its inactivated COVID-19 vaccines triggered a strong neutralizing antibody response in a phase 1/2 study. And even as the design of a phase 3 trial is still under wraps, the company is reportedly offering the experimental vaccine to employees at state-owned companies who intend to travel overseas. read more Tuesday, June 16, 2020 The COVID-19 pandemic should push the industry to consider a new way of thinking about innovation and improvement, journalist and author Malcolm Gladwell said. read more Tuesday, June 16, 2020 The coronavirus pandemic has shown just how much time, effort and cash are required to scale up for new vaccine production. Sanofi is trying to get a head start on that for the next pandemic—and supply its current vaccines at the same time—with a big expansion of its manufacturing capacity. read more Monday, June 15, 2020 Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more Tuesday, June 16, 2020 The U.K. approved dexamethasone for severely-ill COVID patients hours after the release of clinical data. Sanofi will build a new vaccine plant to tackle future pandemics, and Imperial College London and Novavax scored additional funds for their COVID shots. Plus, GlobalData reported that clinical trials are getting back on track, with some caveats. read more Tuesday, June 16, 2020 Verily announced that its COVID-19 testing program has been expanded to more than 130 cities and towns across the U.S. and has provided over 256,000 tests through a growing network of public and private partners. read more Tuesday, June 16, 2020 Device maker Fitbit is the latest technology company to jump into the back-to-work business. Check out the growing list of companies getting into this space and why Fitbit executives think wearables could play an important role in catching early signs of COVID-19 infection. read more Tuesday, June 16, 2020 Pharma is looking to reset its image with COVID-19 vaccines and treatments, but landmines loom—with pricing likely the biggest. It's true that the halo from pharma’s rapid response in R&D has propelled the industry’s reputation to an all-time high. But some tough decisions lurk just beyond the lab. read more Monday, June 15, 2020 The COVID-19 pandemic is starting to reach rural areas as cases in some states start to rise with economies reopening. read more Tuesday, June 16, 2020 Amid the race to develop a COVID-19 vaccine, Novavax has been busy scouting funds and inking deals to prepare for a manufacturing scale-up. That work continued Monday with the company’s $200 million raise through a private placement. read more Tuesday, June 16, 2020 As CROs and biopharmas adapt to virtual trials and conducting tests amid a pandemic, some studies are back up and running, but future approvals will be hit by last quarter’s chaos. read more |
